Page 13 - Flipbook

Confirmed ORR and DOR

60
47%
50 44%

(%) 40

ORR a 30 35% 37% 23%

20
17%
PR: 10
13%
CR: 0 7% 6%

Atezo + Placebo + Atezo
plt/gem plt/gem
b
DOR , median 8.5 7.6 NE
(95% CI), mo (7.2,10.4) (6.3, 8.5) (15.9, NE)

Data cutoff 31 May 2019; median survival follow-up 11.8 months (all patients).
a Objective response–evaluable patients: n = 447 in atezo + plt/gem, n = 397 in placebo + plt/gem, n = 359 in atezo.
b n = 212 in atezo + plt/gem, n = 174 in placebo + plt/gem, n = 82 in atezo.

http://bit.ly/2Z1bPbD
IMvigor130—ESMO 2019 (LBA14): presented by Dr Enrique Grande